# Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)

> **NCT00783471** · PHASE2 · TERMINATED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 51 (actual)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib, Docetaxel
- **DRUG:** Docetaxel, Erlotinib

## Key facts

- **NCT ID:** NCT00783471
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both treatment arms.
- **Last updated:** 2010-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783471, "Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00783471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*